Physician profile
Melissa Clements
NPI 1114079597
$1,731.90
in general payments reported to CMS, 2019-2025
14 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $176 · 2021: $316 · 2022: $181 · 2023: $43.05 · 2024: $556 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $327.28 | 2019-2024 | Bimzelx |
| Pfizer INC. | $285.68 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.80 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $134.64 | 2024 | Zoryve |
| Dermira, INC. | $121.58 | 2019 | |
| Janssen Scientific Affairs, LLC | $120.77 | 2021 | |
| Abbvie INC. | $117.31 | 2024 | |
| Lilly USA, LLC | $91.89 | 2021 | |
| Biofrontera INC. | $48.13 | 2020-2024 | Rhodoled Xl, Ameluz, Xepi |
| Amgen INC. | $28.55 | 2021-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $26.81 | 2025 | Sotyktu |
| Janssen Biotech, INC. | $23.37 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.